KalVista Pharmaceuticals, Inc. (KALV) News
Filter KALV News Items
KALV News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
KALV News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest KALV News From Around the Web
Below are the latest news stories about KALVISTA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate KALV as an investment opportunity.
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass. & SALISBURY, England, January 08, 2025--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) today announced that the compensation committee of KalVista’s board of directors granted nine newly-hired employees inducement options to purchase an aggregate of 61,000 shares of KalVista common stock on January 2, 2025 as inducements material to each employee entering into employment with KalVista. The options have an exercise price that is equal to the closing price of KalVista common stock |
Sector Update: Health Care Stocks Advance in Afternoon TradingHealth care stocks were rising Wednesday afternoon, with the NYSE Health Care Index adding 0.3% and |
KalVista Pharmaceuticals' Sebetralstat Poised to Disrupt Acute HAE Market With Oral Advantage, BofA SaysKalVista Pharmaceuticals' (KALV) drug candidate sebetralstat is a promising, on-demand oral treatmen |
KalVista Appoints Jeb Ledell as Chief Operating OfficerCAMBRIDGE, Mass. & SALISBURY, England, December 16, 2024--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Jeb Ledell has joined the Company as Chief Operating Officer (COO). Mr. Ledell is an accomplished public company COO with a track record of driving operational excellence and strategic growth within the biotechnology industry. |
KalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational UpdateCAMBRIDGE, Mass. & SALISBURY, England, December 05, 2024--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today released financial results for the second fiscal quarter ended October 31, 2024. The Company also provided an operational update, highlighted by the U.S. Food and Drug Administration (FDA) acceptance of a New Drug Application (NDA) for sebetralstat, a novel, investigational treatment for hereditary angioedema (HAE). |
KalVista Pharmaceuticals Appoints Laurence Reid, Ph.D., to Board of DirectorsCAMBRIDGE, Mass. & SALISBURY, England, November 26, 2024--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Laurence Reid, Ph.D., has been appointed to the Company’s Board of Directors, effective immediately. Dr. Reid brings more than three decades of experience with a track record of leadership and company-building success. |
KalVista Pharmaceuticals to Present at Upcoming Investor ConferencesCAMBRIDGE, Mass. & SALISBURY, England, November 12, 2024--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the Company will participate in a fireside chat at each of the following investor conferences: |
KalVista Secures $184M Financing for Sebetralstat LaunchKalVista Pharmaceuticals ( (KALV) ) has provided an update. KalVista Pharmaceuticals has secured a significant up to $184 million synthetic royalty financing deal with DRI Healthcare Trust to fund the commercialization of sebetralstat, a novel oral therapy for hereditary angioedema (HAE). The agreement includes an initial $100 million upfront payment, potential milestone payments, and a tiered royalty structure based on global net sales. This strategic move strengthens KalVista’s financial posit |
DRI Healthcare Trust Acquires Royalty Stake in Global Sales of SebetralstatDRI Healthcare Trust Acquires Royalty Stake in Global Sales of Sebetralstat |
KalVista Pharmaceuticals Announces Pricing of a $55 Million Underwritten Offering of Common Stock and Concurrent Private Placement of $5 MillionCAMBRIDGE, Mass. & SALISBURY, England, November 04, 2024--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) ("KalVista") today announced the pricing of an underwritten offering of 5,500,000 shares of its common stock at a price of $10.00 per share to certain investors (the "Offering"). The gross proceeds to KalVista from the Offering are expected to be $55 million, before deducting underwriting discounts, commissions and other offering expenses payable by KalVista. |